Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans

Journal of Infectious Diseases

Volumn 211, Issue 4, 2015, Pages 518-528

  Baden, Lindsey R ^a,b,c,d   Liu, Jinyan ^b,c   Li, Hualin ^b,c   Johnson, Jennifer A ^a,c   Walsh, Stephen R ^a,b,c   Kleinjan, Jane A ^a   Engelson, Brian A ^a   Peter, Lauren ^b,c   Abbink, Peter ^b,c   Milner, Danny A ^a,c   Golden, Kevin L ^a,c   Viani, Kyle L ^a,c   Stachler, Matthew D ^a,c   Chen, Benjamin J ^a,c   Pau, Maria G ^e   Weijtens, Mo ^e   Carey, Brittany R ^b   Miller, Caroline A ^b   Swann, Edith M ^g   Wolff, Mark ^f   Loblein, Hayley ^f   Seaman, Michael S ^b,c,d   Dolin, Raphael ^a,b,c,d   Barouch, Dan H ^b,c,d   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e CRUCELL HOLLAND BV   (Netherlands)

^f EMMES CORPORATION   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

adenovirus; HIV; mucosal immunity; vaccine

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADENOVIRIDAE; ADULT; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFLAMMATION; MALE; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECTUM BIOPSY; SAMPLING; SEROTYPE; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS ENVELOPE; VIRUS RECOMBINANT; VOLUNTEER; BLOOD; CLINICAL TRIAL; COLON; ENZYME LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMAN ADENOVIRUS C; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INTESTINE MUCOSA; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MUCOSAL IMMUNITY; PATHOLOGY; YOUNG ADULT;

ADENOVIRUSES, HUMAN; ADULT; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; COLON; CYTOKINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; INJECTIONS, INTRAMUSCULAR; INTESTINAL MUCOSA; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84922429103     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu485     Document Type: Article

References (29)

1. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
3. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
4. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083-92.
5. Perreau M, Welles HC, Harari A, et al. DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mu-cosa. J Virology 2011; 85:9854-62.
6. Baden LR, Walsh SR, Seaman MS, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013; 207:240-7.
7. Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013; 207:248-56.
8. Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiol-ogy of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011; 29:5203-9.
9. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950-7.
10. Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, Barouch DH. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 2012; 86:10862-5.
11. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132:397-409.
12. Perreau M, Welles HC, Pellaton C, et al. The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J Virol 2012; 86:6279-85.
13. Penaloza-MacMaster P, Provine NM, Ra J, et al. Alternative serotype ad-enovirus vaccine vectors elicit memory T cells with enhanced anamnes-tic capacity compared to Ad5 vectors. J Virol 2013; 87:1373-84.
14. Tan WG, Jin HT, West EE, et al. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol 2013; 87:1359-72.
15. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
16. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011; 3:81ra36.
17. Li H, Liu J, Carville A, Mansfield KG, Lynch D, Barouch DH. Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J Virol 2011; 85:11007-15.
18. Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and het-erologous prime-boost regimens in rhesus monkeys. J Virol 2008; 82:4844-52.
19. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.
20. Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Micro-biol 2003; 41:5046-52.
21. Masek-Hammerman K, Li H, Liu J, et al. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 2010; 84:9810-6.
22. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15:873-5.
23. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009; 15:876-8.
24. Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012; 122:359-67.
25. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905.
26. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP. Immunology. Immune activation with HIV vaccines. Science 2014; 344:49-51.
27. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11:507-15.
28. Duerr A, Huang Y, Buchbinder S, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recom-binant adenovirus HIV vaccine (Step Study). J Infect Dis 2012; 206:258-66.
29. Bukh I, Calcedo R, Roy S, et al. Increased mucosal CD4+ T cell activation following vaccination with an adenoviral vector in rhesus macaques. J Virol 2014; 88:8468-78.